November 11, 2024

Early Data for Phase 1 TNBC Vaccine Trial

Novel vaccine targeting alpha-lactalbumin, a protein expressed in 70% of triple-negative breast cancers but otherwise found only in lactating breast tissue, shows early immune response in Phase 1 trial.

Conexiant

November 08, 2024

Eyeing the Future of Oncology: Highlights From the Presidential Symposium at ESMO Congress 2024

At the European Society for Medical Oncology (ESMO) Congress 2024, the Eyes to the Future Presidential Symposium showcased innovative approaches in personalized medicine, immunotherapy resistance, and...

The ASCO Post

November 07, 2024

Words That Shut Down Patient Conversations

Certain words can unintentionally disempower patients, according to a perspective outlining language clinicians should avoid in conversations with seriously ill patients.

Conexiant

November 05, 2024

Catholic Hospitals Shift to Megacorporations as Nuns Vanish

Discover how the original mission of Catholic hospitals led by nuns has transformed into a question of identity and purpose in modern healthcare.

KFF Health News

November 04, 2024

FTC Finalizes "Click-to-Cancel" Rule

FTC finalizes rule requiring subscription-based businesses to provide cancellation processes as simple as enrollment methods, effective 180 days after Federal Register publication.

Conexiant

October 28, 2024

ECOG-ACRIN Cancer Research Group, Caris Life Sciences Partner to Learn More From TAILORx Trial

The ECOG-ACRIN Cancer Research Group and Caris Life Sciences announced a new multiyear research collaboration that will begin with the interrogation of the TAILORx trial.

The ASCO Post

October 28, 2024

Immunotherapy Plus Targeted Therapy for Anaplastic Thyroid Carcinoma

Researchers have examined whether anti–PD-L1 immunotherapy combined with mutation-directed targeted therapy could extend overall survival in patients with anaplastic thyroid carcinoma.

The ASCO Post

October 24, 2024

CABINET Trial Supports Multitargeted Tyrosine Kinase Inhibitor for Advanced Neuroendocrine Tumors

The multicenter phase III CABINET trial has shown significantly improved progression-free survival with the multitargeted tyrosine kinase inhibitor cabozantinib vs placebo in previously treated patien...

The ASCO Post

October 23, 2024

Risk of Subsequent Neoplasms in Survivors of Childhood Neuroblastoma

In a Dutch study reported in the Journal of Clinical Oncology, Westerveld et al identified long-term risks of subsequent neoplasms in 5-year survivors of childhood neuroblastoma.

The ASCO Post